Cognitive impairment, neuroimaging, and Alzheimer neuropathology in mouse models of down syndrome

Current Alzheimer Research

Volumn 13, Issue 1, 2016, Pages 35-52

  Hamlett, Eric D ^a   Boger, Heather A ^a   Ledreux, Aurélie ^a   Kelley, Christy M ^b   Mufson, Elliott J ^c   Falangola, Maria F ^a   Guilfoyle, David N ^d   Nixon, Ralph A ^d   Patterson, David ^e   Duval, Nathan ^e   Granholm, Ann Charlotte E ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c BARROW NEUROLOGICAL INSTITUTE   (United States)

^d NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^e UNIVERSITY OF DENVER   (United States)

Author keywords

Cholinergic neurons; Diffusional kurtosis imaging; Down syndrome; Intellectual disability; Memory loss; Neuro inflammation

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; ALPHA TOCOPHEROL; AMYLOID; AMYLOID PRECURSOR PROTEIN; BENZYL[3 [[1 (3,4 DICHLOROPHENYL)ETHYL]AMINO] 2 HYDROXYPROPYL]PHOSPHINIC ACID; CHOLINESTERASE INHIBITOR; DONEPEZIL; DONEPEZIL PLUS MEMANTINE; DROXIDOPA; EPIGALLOCATECHIN GALLATE; ESTROGEN; FLUOXETINE; GALANTAMINE; MEMANTINE; PENTETRAZOLE; RIVASTIGMINE; TAU PROTEIN;

AGE; AGING; ALZHEIMER DISEASE; AMNESIA; AMYLOIDOSIS; ARTICLE; BEHAVIOR DISORDER; CELL LOSS; CHOLINERGIC NERVE CELL; COGNITIVE DEFECT; DIFFUSION TENSOR IMAGING; DOWN SYNDROME; FOREBRAIN; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; LEARNING; MEMORY; MORRIS WATER MAZE TEST; MOUSE MODEL; NERVE CELL DEGENERATION; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SPATIAL MEMORY; TAUOPATHY; ANIMAL; COGNITION DISORDERS; COMPLICATION; DISEASE MODEL; GENETICS; MOUSE; PATHOLOGY;

ALZHEIMER DISEASE; ANIMALS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOWN SYNDROME; HUMANS; MICE; NEUROIMAGING; NEUROPATHOLOGY;

EID: 84953439283     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205012666150921095505     Document Type: Article

References (205)

1. Hassold T, Sherman S. Down syndrome: genetic recombination and the origin of the extra chromosome 21. Clin Genet 57(2): 95-100 (2000).
2. Presson AP, Partyka G, Jensen KM, Devine OJ, Rasmussen SA, McCabe LL, et al. Current estimate of Down Syndrome population prevalence in the United States. J Pediatr 163(4): 1163-8 (2013).
3. Lott IT, Dierssen M. Cognitive deficits and associated neurological complications in individuals with Down's syndrome. Lancet Neurol 9(6): 623-33 (2010).
4. Head E, Silverman W, Patterson D, Lott IT. Aging and down syndrome. Curr Gerontol Geriatr Res 2012: 412536 (2012).
5. Hartley D, Blumenthal T, Carrillo M, DiPaolo G, Esralew L, Gardiner K, et al. Down syndrome and Alzheimer's disease: Common pathways, common goals. Alzheimers Dement 11(6): 700-9 (2015).
6. Lai F., Williams RS. A prospective study of Alzheimer disease in Down syndrome. Arch Neurol 46(8): 849-53 (1989).
7. Wisniewski KE, Dalton AJ, McLachlan C, Wen GY, Wisniewski HM. Alzheimer's disease in Down's syndrome: clinicopathologic studies. Neurology 35(7): 957-61 (1985).
8. Lai F. Clinicopathologic features of Alzheimer disease in Down syndrome. Prog Clin Biol Res 379: 15-34 (1992).
9. Menendez M. Down syndrome, Alzheimer's disease and seizures. Brain Dev 27(4): 246-52 (2005).
10. Rubinsztein DC, Hon J, Stevens F, Pyrah I, Tysoe C, Huppert FA, et al. Apo E genotypes and risk of dementia in Down syndrome. Am J Med Genet 88(4): 344-347 (1999).
11. Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res 221(2): 555-63 (2010).
12. Sanchez MM, Moghadam S, Naik P, Martin KJ, Salehi A.Hippocampal network alterations in Alzheimer's disease and Down syndrome: from structure to therapy. J Alzheimers Dis 26(3): 29-47 (2011).
13. Ferrer I, Gullotta F. Down's syndrome and Alzheimer's disease: dendritic spine counts in the hippocampus. Acta Neuropathol 79(6): 680-5 (1990).
14. Iulita MF, Cuello AC. Nerve growth factor metabolic dysfunction in Down's syndrome brains. Brain 137(3): 860-72 (2014).
15. Garcia-Cerro S, Martinez P, Vidal V, Corrales A, Florez J, Vidal R, et al. Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of Down syndrome. PLoS One 9(9): e106572 (2014).
16. Cataldo AM, Petanceska S, Terio NB, Peterhoff CM, Durham R, Mercken M, et al. Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. Neurobiol Aging 25(10): 1263-72 (2004).
17. Wilcock DM. Neuroinflammation in the aging down syndrome brain: lessons from Alzheimer's disease. Curr Gerontol Geriatr Res 2012: 170276 (2012).
18. Lott IT, Head E, Doran E, Busciglio J. Beta-amyloid, oxidative stress and down syndrome. Curr Alzheimer Res 3(5): 521-8 (2006).
19. Mann DM, Esiri MM. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J Neurol Sci 89(2-3): 169-79 (1989).
20. Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ. Sequence of deposition of heterogeneous amyloid betapeptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 3(1): 16-32 (1996).
21. Head E, Powell D, Gold BT, Schmitt FA. Alzheimer's Disease in Down Syndrome. Eur J Neurodegener Dis 1(3): 353-364 (2012).
22. Hunter CL, Bimonte-Nelson HA, Nelson M, Eckman CB, Granholm AC. Behavioral and neurobiological markers of Alzheimer's disease in Ts65Dn mice: effects of estrogen. Neurobiol Aging 25(7): 873-84 (2004).
23. Hunter CL, Bimonte-Nelson HA, Granholm AC. Behavioral comparison of 4 and 6 month-old Ts65Dn mice: age-related impairments in working and reference memory. Behav Brain Res 138(2): 121-31 (2003).
24. Choi JH, Berger JD, Mazzella MJ, Morales-Corraliza J, Cataldo AM, Nixon RA, et al. Age-dependent dysregulation of brain amyloid precursor protein in the Ts65Dn Down syndrome mouse model. J Neurochem 110(6): 1818-27 (2009).
25. Cataldo AM, Petarceska S, Peterhoff CM, Terio NB, Epsteir CJ, Villar A, et al. App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome. J Neurosci 23(17): 6788-92 (2003).
26. Lomoio, S, Scherini E, Necchi D. Beta-amyloid overload does not directly correlate with SAPK/JNK activation and tau protein phosphorylation in the cerebellar cortex of Ts65Dn mice. Brain Res 1297: 198-206 (2009).
27. Cardenas AM, Ardiles AO, Barraza N, Baez-Matus X, Caviedes P. Role of tau protein in neuronal damage in Alzheimer's disease and Down syndrome. Arch Med Res 43(8): 645-54 (2012).
28. Hof PR, Bouras C, Perl DP, Sparks DL, Mehta N, Morrison JH. Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down's syndrome. Quantitative regional analysis and comparison with Alzheimer's disease. Arch Neurol 52(4): 379-91 (1995).
29. Mann DM, Yates PO, Marcyniuk B. Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle age form an age related continuum of pathological changes. Neuropathol Appl Neurobiol 10(3): 185-207 (1984).
30. Mann DM, Yates PO, Marcyniuk B, Ravindra CR. The topography of plaques and tangles in Down's syndrome patients of different ages. Neuropathol Appl Neurobiol 12(5): 447-57 (1986).
31. Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 17(3): 278-82 (1985).
32. Wisniewski HM, Rabe A. Discrepancy between Alzheimer-type neuropathology and dementia in persons with Down's syndrome. Ann N Y Acad Sci 477: 247-60 (1986).
33. Schupf N, Sergievsky GH. Genetic and host factors for dementia in Down's syndrome. Br J Psychiatry 180: 405-10 (2002).
34. Sturgeon X, Gardiner KJ. Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions. Mamm Genom 22(5-6): 261-71 (2011).
35. Busciglio J, Capone G, O'Bryan J, Gardiner KJ. Down syndrome: genes, model systems, and progress towards pharmacotherapies and clinical trials for cognitive deficits. Cytogenet Genom Res 141(4): 260-71 (2013).
36. Gardiner K, Fortna A, Bechtel L, Davisson MT. Mouse models of Down syndrome: how useful can they be? Comparison of the gene content of human chromosome 21 with orthologous mouse genomic regions. Gene 318: 137-47 (2003).
37. Reeves RH, Irving NG, Moran TH, Wohn A, Kitt C, Sisodia SS, et al. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet 11(2): 177-84 (1995).
38. Cooper JD, Salehi A, Delcroix JD, Howe CL, Belichenko PV, Chua-Couzens J, et al. Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc Natl Acad Sci U S A 98(18): 10439-44 (2001).
39. Granholm AC, Sanders LA, Crnic LS. Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome. Exp Neurol 161(2): 647-63 (2000).
40. Holtzman DM, Santucci D, Kilbridge J, Chua-Couzens J, Fontana DJ, Daniels SE, et al. Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc Natl Acad Sci U S A 93(23): 13333-8 (1996).
41. Insausti AM, Megias M, Crespo D, Cruz-Orive LM, Dierssen M, Vallina IF, et al. Hippocampal volume and neuronal number in Ts65Dn mice: a murine model of Down syndrome. Neurosci Lett 253(3): 175-8 (1998).
42. Siarey RJ, Stoll J, Rapoport SI, Galdzicki Z. Altered long-term potentiation in the young and old Ts65Dn mouse, a model for Down Syndrome. Neuropharmacology 36(11-12): 1549-54 (1997).
43. Hunter CL, Isacson O, Nelson M, Bimonte-Nelson H, Seo H, Lin L, et al. Regional alterations in amyloid precursor protein and nerve growth factor across age in a mouse model of Down's syndrome. Neurosci Res 45(4): 437-45 (2003).
44. Seo H, Isacson O. Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice. Exp Neurol 193(2): 469-80 (2005).
45. Haydar TF, Blue ME, Molliver ME, Krueger BK, Yarowsky PJ. Consequences of trisomy 16 for mouse brain development: corticogenesis in a model of Down syndrome. J Neurosci 16(19): 6175-82 (1996).
46. Bambrick LL, Krueger BK. Neuronal apoptosis in mouse trisomy 16: mediation by caspases. J Neurochem 72(4): 1769-72 (1999).
47. Davisson MT, Schmidt C, Akeson EC. Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome. Prog Clin Biol Res 360: 263-80 (1990).
48. Duchon A, Raveau M, Chevalier C, Nalesso V, Sharp AJ, Herault Y. Identification of the translocation breakpoints in the Ts65Dn and Ts1Cje mouse lines: relevance for modeling Down syndrome. Mamm Genome 22(11-12): 674-84 (2011).
49. Sanders NC, Williams DK, Wenger GR. Does the learning deficit observed under an incremental repeated acquisition schedule of reinforcement in Ts65Dn mice, a model for Down syndrome, change as they age? Behav Brain Res 203(1): 137-42 (2009).
50. Ishihara K, Amano K, Takaki E, Ebrahim AS, Shimohata A, Shibazaki N, et al. Increased lipid peroxidation in Down's syndrome mouse models. J Neurochem 110(6): 1965-76 (2009).
51. Shukkur EA, Shimohata A, Akagi T, Yu W, Yamaguchi M, Murayama M, et al. Mitochondrial dysfunction and tau hyperphosphorylation in Ts1Cje, a mouse model for Down syndrome. Hum Mol Genet 15(18): 2752-62 (2006).
52. Belichenko NP, Belichenko PV, Kleschevnikov AM, Salehi A, Reeves RH, Mobley WC. The "Down syndrome critical region" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome. J Neurosci 29(18): 5938-48 (2009).
53. Sago H, Carlson EJ, Smith DJ, Rubin EM, Crnic LS, Huang TT, et al. Genetic dissection of region associated with behavioral abnormalities in mouse models for Down syndrome. Pediatr Res 48(5): 606-13 (2000).
54. Lockrow J, Boger H, Bimonte-Nelson H, Granholm AC. Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Behav Brain Res 221(2): 610-22 (2010).
55. Salehi A, Delcroix JD, Belichenko PV, Zhan K, Wu C, Valletta JS, et al. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 51(1): 29-42 (2006).
56. Cataldo AM, Mathews PM, Boiteau AB, Hassinger LC, Peterhoff CM, Jiang Y, et al. Down syndrome fibroblast model of Alzheimer-related endosome pathology: accelerated endocytosis promotes late endocytic defects. Am J Pathol 173(2): 370-84 (2008).
57. Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol 157(1): 277-86 (2000).
58. Levine S, Saltzman A, Levy E, Ginsberg SD. Systemic pathology in aged mouse models of Down's syndrome and Alzheimer's disease. Exp Mol Pathol 86(1): 18-22 (2009).
59. Villar AJ, Belichenko PV, Gillespie AM, Kozy HM, Mobley WC, Epstein CJ. Identification and characterization of a new Down syndrome model, Ts[Rb(12.1716)]2Cje, resulting from a spontaneous Robertsonian fusion between T(171)65Dn and mouse chromosome 12. Mamm Genom 16(2): 79-90 (2005).
60. Yu T, Li Z, Jia Z, Clapcote SJ, Liu C, Li S, et al. A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions. Hum Mol Genet 19(14): 2780-91 (2010).
61. Zhang L, Meng K, Jiang X, Liu C, Pao A, Belichenko PV, et al. Human chromosome 21 orthologous region on mouse chromosome 17 is a major determinant of Down syndrome-related developmental cognitive deficits. Hum Mol Genet 23(3): 578-89 (2014).
62. Ahmed MM, Dhanasekaran AR, Tong S, Wiseman FK, Fisher EM, Tybulewicz VL, et al. Protein profiles in Tc1 mice implicate novel pathway perturbations in the Down syndrome brain. Hum Mol Genet 22(9): 1709-24 (2013).
63. Gribble SM, Wiseman FK, Clayton S, Prigmore E, Langley E, Yang F, et al. Massively parallel sequencing reveals the complex structure of an irradiated human chromosome on a mouse background in the Tc1 model of Down syndrome. PLoS One 2013. 8(4): p. e60482.
64. Singh P, Schimenti JC, Bolcun-Filas E. A mouse geneticist's practical guide to CRISPR applications. Genetics 199(1): 1-15 (2015).
65. Driscoll LL, Carroll JC, Moon J, Crnic LS, Levitsky DA, Strupp BJ. Impaired sustained attention and error-induced stereotypy in the aged Ts65Dn mouse: a mouse model of Down syndrome and Alzheimer's disease. Behav Neurosci 118(6): 1196-205 (2004).
66. Hyde LA, Crnic LS. Age-related deficits in context discrimination learning in Ts65Dn mice that model Down syndrome and Alzheimer's disease. Behav Neurosci 115(6): 1239-46 (2001).
67. Demas GE, Nelson RJ, Krueger BK, Yarowsky PJ. Spatial memory deficits in segmental trisomic Ts65Dn mice. Behav Brain Res 82(1): 85-92 (1996).
68. Bimonte-Nelson HA, Hunter CL, Nelson ME, Granholm AC. Frontal cortex BDNF levels correlate with working memory in an animal model of Down syndrome. Behav Brain Res 139(1-2): 47-57 (2003).
69. Demas GE, Nelson RJ, Krueger BK, Yarowsky PJ. Impaired spatial working and reference memory in segmental trisomy (Ts65Dn) mice. Behav Brain Res 90(2): 199-201 (1998).
70. Lockrow J, Prakasam A, Huang P, Bimonte-Nelson H, Sambamurti K, Granholm AC. Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model. Exp Neurol 216(2): 278-89 (2009).
71. Fernandez F, Garner CC. Episodic-like memory in Ts65Dn, a mouse model of Down syndrome. Behav Brain Res 188(1): 233-7 (2008).
72. Costa AC, Stasko MR, Schmidt C, Davisson MT. Behavioral validation of the Ts65Dn mouse model for Down syndrome of a genetic background free of the retinal degeneration mutation Pde6b(rd1). Behav Brain Res 206(1): 52-62 (2010).
73. Stasko MR, Costa AC. Experimental parameters affecting the Morris water maze performance of a mouse model of Down syndrome. Behav Brain Res 154(1): 1-17 (2004).
74. Escorihuela RM, Vallina IF, Martinez-Cue C, Baamonde C, Dierssen M, Tobena A, et al. Impaired short-and long-term memory in Ts65Dn mice, a model for Down syndrome. Neurosci Lett 247(2-3): 171-4 (1998).
75. Whitney KN, Wenger GR. Impulsivity and motor activity in aged, male Ts65Dn mice. Exp Clin Psychopharmacol 21(5): 345-54 (2013).
76. Sabbagh MN, Chen K, Rogers J, Fleisher AS, Liebsack C, Bandy D, et al. Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementia. Alzheimers Dement pii: S1552-5260(15): 84-9 (2015).
77. Handen BL, Cohen AD, Channamalappa U, Bulova P, Cannon SA, Cohen WI, et al. Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. Alzheimers Dement 8(6): 496-501 (2012).
78. Carducci F, Onorati P, Condoluci C, Di Gennaro G, Quarato PP, Pierallini A, et al. Whole-brain voxel-based morphometry study of children and adolescents with Down syndrome. Funct Neurol 28(1): 19-28 (2013).
79. d'Abrera JC, Holland AJ, Landt J, Stocks-Gee G, Zaman SH. A neuroimaging proof of principle study of Down's syndrome and dementia: ethical and methodological challenges in intrusive research. J Intellect Disabil Res 57(2): 105-118 (2013).
80. Jacola LM, Byars AW, Hickey F, Vannest J, Holland SK, Schapiro MB. Functional magnetic resonance imaging of story listening in adolescents and young adults with Down syndrome: evidence for atypical neurodevelopment. J Intellect Disabil Res 58(10): 892-902 (2014).
81. Hartley SL, Handen BL, Devenny DA, Hardison R, Mihaila I, Price JC, et al. Cognitive functioning in relation to brain amyloid-β in healthy adults with Down syndrome. Brain 137(Pt 9): 2556-63 (2014).
82. Imai M, Watanabe H, Yasui K, Kimura Y, Shitara Y, Tsuchida S, et al. Functional connectivity of the cortex of term and preterm infants and infants with Down's syndrome. Neuroimage 85: 272-278 (2014).
83. Powell D, Caban-Holt A, Jicha G, Robertson W, Davis R, Gold BT, et al. Frontal white matter integrity in adults with Down syndrome with and without dementia. Neurobiol Aging 35(7): 1562-9 (2014).
84. Vega JN, Hohman TJ, Pryweller JR, Dykens EM, Thornton-Wells TA. Resting-state functional connectivity in individuals with down syndrome and williams syndrome compared with typically developing controls. Brain Connect (2015); [Epub ahead of print].
85. Chen Y, Dyakin VV, Branch CA, Ardekani B, Yang D, Guilfoyle DN, et al. In vivo MRI identifies cholinergic circuitry deficits in a Down syndrome model. Neurobiol Aging 30(9): 1453-65 (2009).
86. Ishihara K, Amano K, Takaki E, Shimohata A, Sago H, Epstein CJ, et al. Enlarged brain ventricles and impaired neurogenesis in the Ts1Cje and Ts2Cje mouse models of Down syndrome. Cereb Cortex 20(5): 1131-43 (2010).
87. Santin MD, Valabregue R, Rivals I, Penager R, Paquin R, Dauphinot L, et al. In vivo 1H MRS study in microlitre voxels in the hippocampus of a mouse model of Down syndrome at 11.7 T. NMR Biomed 27(10): 1143-50 (2014).
88. Kaur G, Sharma A, Xu W, Gerum S, Alldred MJ, Subbanna S, et al. Glutamatergic transmission aberration: a major cause of behavioral deficits in a murine model of Down's syndrome. J Neurosci 34(15): 5099-106 (2014).
89. Nie X, Hamlett ED, Granholm AC, Hui ES, Helpern JA, Jensen JH, et al. Evidence of altered age-related brain cytoarchitecture in mouse models of down syndrome: a diffusional kurtosis imaging study. Magn Reson Imaging 33(4): 437-47 (2014).
90. Jensen JH, Helpern JA, Ramani A, Lu H, Kaczynski K. Diffusional kurtosis imaging: the quantification of non-gaussian water diffusion by means of magnetic resonance imaging. Magn Reson Med 53(6): 1432-40 (2005).
91. Lu H, Jensen JH, Ramani A, Helpern JA. Three-dimensional characterization of non-gaussian water diffusion in humans using diffusion kurtosis imaging. NMR Biomed 19(2): 236-47 (2006).
92. Jensen JH, Helpern JA. MRI quantification of non-Gaussian water diffusion by kurtosis analysis. NMR Biomed 23(7): 698-710 (2010).
93. heung MM, Hui ES, Chan KC, Helpern JA, Qi L, Wu EX. Does diffusion kurtosis imaging lead to better neural tissue characterization? A rodent brain maturation study. Neuroimage 45(2): 386-92 (2009).
94. Vanhoutte G, Pereson S, Delgado Y Palacios R, Guns PJ, Asselbergh B, et al. Diffusion kurtosis imaging to detect amyloidosis in an APP/PS1 mouse model for Alzheimer's disease. Magn Reson Med 69(4): 1115-21 (2013).
95. Grinberg F, Farrher E, Ciobanu L, Geffroy F, Le Bihan D, Shah NJ. Non-Gaussian diffusion imaging for enhanced contrast of brain tissue affected by ischemic stroke. PLoS One 9(2): e89225 (2014).
96. Weber RA, Hui ES, Jensen JH, Nie X, Falangola MF, Helpern JA, et al. Diffusional kurtosis and diffusion tensor imaging reveal different time-sensitive stroke-induced microstructural changes. Stroke 46(2): 545-50 (2015).
97. Falangola MF, Guilfoyle DN, Tabesh A, Hui ES, Nie X, Jensen JH, et al. Histological correlation of diffusional kurtosis and white matter modeling metrics in cuprizone-induced corpus callosum demyelination. NMR Biomed 27(8): 948-57 (2014).
98. Belichenko PV, Masliah E, Kleschevnikov AM, Villar AJ, Epstein CJ, Salehi A, et al. Synaptic structural abnormalities in the Ts65Dn mouse model of Down Syndrome. J Comp Neurol 480(3): 281-98 (2004).
99. Popov VI, Kleschevnikov AM, Klimenko OA, Stewart MG, Belichenko PV. Three-dimensional synaptic ultrastructure in the dentate gyrus and hippocampal area CA3 in the Ts65Dn mouse model of Down syndrome. J Comp Neurol 519(7): 1338-54 (2011).
100. Abraham H, Vincze A, Veszpremi B, Kravjak A, Gomori E, Kovacs GG, et al. Impaired myelination of the human hippocampal formation in Down syndrome. Int J Dev Neurosci 30(2): 147-58 (2012).
101. Wisniewski KE, Schmidt-Sidor B. Postnatal delay of myelin formation in brains from Down syndrome infants and children. Clin Neuropathol 8: 55-62 (1989).
102. Gardiner KJ. Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations. Drug Des Develop Ther 9: 103-125 (2015).
103. Lockrow JP, Fortress AM, Granholm AC. Age-related neurodegeneration and memory loss in down syndrome. Curr Gerontol Geriatr Res 2012: 463909 (2012).
104. McGeer PL. The 12th J. A. F. Stevenson memorial lecture. Aging, Alzheimer's disease, and the cholinergic system. Can J Physiol Pharmacol 62(7): 741-54 (1984).
105. Perry E, Walker M, Grace J, Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci 22(6): 273-80 (1999).
106. Dunnett SB, Everitt BJ, Robbins TW. The basal forebrain-cortical cholinergic system: interpreting the functional consequences of excitotoxic lesions. Trends Neurosci 14(11): 494-501 (1991).
107. Ikonomovic MD, Mufson EJ, Wuu J, Cochran EJ, Bennett DA, DeKosky ST. Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: correlation with Alzheimer's neuropathology. J Alzheimers Dis 5(1): 39-48 (2003).
108. Isacson O, Seo H, Lin L, Albeck D, Granholm AC. Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and ACh. Trends Neurosci 25(2): 79-84 (2002).
109. Yates CM, Simpson J, Gordon A, Maloney AF, Allison Y, Ritchie IM, et al. Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and Down's syndrome. Brain Res 280(1): 119-26 (1983).
110. Mann DM, Yates PO, Marcyniuk B, Ravindra CR. Pathological evidence for neurotransmitter deficits in Down's syndrome of middle age. J Ment Defic Res 29(Pt 2): 125-35 (1985).
111. Contestabile A, Fila T, Bartesaghi R, Contestabile A, Ciani E. Choline acetyltransferase activity at different ages in brain of Ts65Dn mice, an animal model for Down's syndrome and related neurodegenerative diseases. J Neurochem 97(2): 515-26 (2006).
112. Kelley CM, Powers BE, Velazquez R, Ash JA, Ginsberg SD, Strupp BJ, et al. Sex differences in the cholinergic basal forebrain in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease. Brain Pathol 24(1): 33-44 (2014).
113. Coppus AM, Evenhuis HM, Verberne GJ, Visser FE, Eikelenboom P, van Gool WA, et al. Early age at menopause is associated with increased risk of dementia and mortality in women with Down syndrome. J Alzheimers Dis 19(2): 545-50 (2010).
114. Granholm AC, Ford KA, Hyde LA, Bimonte HA, Hunter CL, Nelson M, et al. Estrogen restores cognition and cholinergic phenotype in an animal model of Down syndrome. Physiol Behav 77(2-3): 371-85 (2002).
115. Lally G, Faull RL, Waldvogel HJ, Ferrari S, Emson PC. Calcium homeostasis in ageing: studies on the calcium binding protein calbindin D28K. J Neural Transm 104(10): 1107-12 (1997).
116. Sutherland MK, Wong L, Somerville MJ, Yoong LK, Bergeron C, Parmentier M, et al. Reduction of calbindin-28k mRNA levels in Alzheimer as compared to Huntington hippocampus. Brain Res Mol Brain Res 18(1-2): 32-42 (1993).
117. Pappas IS, Parnavelas JG. Neurotrophins and basic fibroblast growth factor induce the differentiation of calbindin-containing neurons in the cerebral cortex. Exp Neurol 144(2): 302-14 (1997).
118. Iulita MF, Claudio Cuello CA. The NGF metabolic pathway in the CNS and its dysregulation in down syndrome and Alzheimer's disease. Curr Alzheimer Res. 2015.
119. Chan-Palay V. Alterations in the locus coeruleus in dementias of Alzheimer's and Parkinson's disease. Prog Brain Res 88: 625-30 (1991).
120. Whitehouse PJ, Struble RG, Hedreen JC, Clark AW, Price DL. Alzheimer's disease and related dementias: selective involvement of specific neuronal systems. CRC Crit Rev Clin Neurobiol 1(4): 319-39 (1985).
121. Tomlinson BE, Irving D, Blessed G. Cell loss in the locus coeruleus in senile dementia of Alzheimer type. J Neurol Sci 49(3): 419-28 (1981).
122. Mann DM, Yates PO, Marcyniuk B. A comparison of changes in the nucleus basalis and locus caeruleus in Alzheimer's disease. J Neurol Neurosurg Psychiatry 47(2): 201-3 (1984).
123. Haglund M, Sjobeck M, Englund E. Locus ceruleus degeneration is ubiquitous in Alzheimer's disease: possible implications for diagnosis and treatment. Neuropathology 26(6): 528-32 (2006).
124. Heneka MT, Nadrigny F, Regen T, Martinez-Hernandez A, Dumitrescu-Ozimek L, Terwel D, et al. Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci U S A 107(13): 6058-63 (2010).
125. Feinstein DL, Heneka MT, Gavrilyuk V, Dello Russo C, Weinberg G, Galea E. Noradrenergic regulation of inflammatory gene expression in brain. Neurochem Int 41(5): 357-65 (2002).
126. Jardanhazi-Kurutz D, Kummer MP, Terwel D, Vogel K, Dyrks T, Thiele A, et al. Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits. Neurochem Int 57(4): 375-82 (2010).
127. Kalinin S, Gavrilyuk V, Polak PE, Vasser R, Zhao J, Heneka MT, et al. Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol Aging 28(8): 1206-14 (2007).
128. Lockrow J, Boger H, Gerhardt G, Aston-Jones G, Bachman D, Granholm AC. A noradrenergic lesion exacerbates neurodegeneration in a Down syndrome mouse model. J Alzheimers Dis 23(3): 471-89 (2011).
129. Counts SE, Mufson EJ. Noradrenaline activation of neurotrophic pathways protects against neuronal amyloid toxicity. J Neurochem 113(3): 649-60 (2010).
130. Marien MR, Colpaert FC, Rosenquist AC. Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res Brain Res Rev 45(1): 38-78 (2004).
131. Wenk GL, McGann K, Hauss-Wegrzyniak B, Rosi S. The toxicity of tumor necrosis factor-alpha upon cholinergic neurons within the nucleus basalis and the role of norepinephrine in the regulation of inflammation: implications for Alzheimer's disease. Neuroscience 121(3): 719-29 (2003).
132. Rizk P, Salazar J, Raisman-Vozari R, Marien M, Ruberg M, Colpaert F, et al. The alpha2-adrenoceptor antagonist dexefaroxan enhances hippocampal neurogenesis by increasing the survival and differentiation of new granule cells. Neuropsychopharmacology 31(6): 1146-57 (2006).
133. Decker MW, McGaugh JL. Effects of concurrent manipulations of cholinergic and noradrenergic function on learning and retention in mice. Brain Res 477(1-2): 29-37 (1989).
134. Harley C. Noradrenergic and locus coeruleus modulation of the perforant path-evoked potential in rat dentate gyrus supports a role for the locus coeruleus in attentional and memorial processes. Prog Brain Res 88: 307-21 (1991).
135. Gibbs ME, Summers RJ. Role of adrenoceptor subtypes in memory consolidation. Prog Neurobiol 67(5): 345-91 (2002).
136. Salehi A, Faizi M, Colas D, Valletta J, Laguna J, Takimoto-Kimura R, et al. Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. Sci Transl Med 1(7): 7ra17 (2009).
137. Fortress AM, Hamlett ED, Vazey EM, Aston-Jones G, Cass WA, Boger HA, et al. Designer receptors enhance memory in a mouse model of down syndrome. J Neurosci 35(4): 1343-53 (2015).
138. Kalinin S, Polak PE, Madrigal JL, Gavrilyuk V, Sharp A, Chauhan N, et al. Beta-amyloid-dependent expression of NOS2 in neurons: prevention by an alpha2-adrenergic antagonist. Antioxid Redox Signal 8(5-6): 873-83 (2006).
139. Milstein JA, Lehmann O, Theobald DE, Dalley JW, Robbins TW. Selective depletion of cortical noradrenaline by anti-dopamine beta-hydroxylase-saporin impairs attentional function and enhances the effects of guanfacine in the rat. Psychopharmacology (Berl) 190(1): 51-63 (2007).
140. Bosboom JL, Stoffers D, Wolters ECh. Cognitive dysfunction and dementia in Parkinson's disease. J Neural Transm 111(10-11): 1303-15 (2004).
141. Asherson P, Stes S, Nilsson Markhed M, Berggren L, Svanborg P, Kutzelnigg A, et al. The effects of atomoxetine on emotional control in adults with ADHD: An integrated analysis of multicenter studies. Eur Psychiatry 30(4): 511-20 (2015).
142. Lanfranchi S, Jerman O, Dal Pont E, Alberti A, Vianello R. Executive function in adolescents with Down Syndrome. J Intellect Disabil Res 54(4): 308-19 (2010).
143. Beyreuther K, Dyrks T, Hilbich C, Monning U, Konig G, Multhaup G, et al. Amyloid precursor protein (APP) and beta A4 amyloid in Alzheimer's disease and Down syndrome. Prog Clin Biol Res 379: 159-82 (1992).
144. Cork LC. Neuropathology of Down syndrome and Alzheimer disease. Am J Med Genet Suppl 7: 282-6 (1990).
145. Jiang Y, Mullaney KA, Peterhoff CM, Che S, Schmidt SD, Boyer-Boiteau A, et al. Alzheimer's-related endosome dysfunction in Down syndrome is Aβ-independent but requires APP and is reversed by BACE-1 inhibition. Proc Natl Acad Sci 107(4): 1630-35 (2010).
146. Kim S, Sato Y, Mohan PS, Peterhoff C, Pensalfini A, Rigoglioso A, et al. Evidence that the Rab5 effector APPL1 mediates APP-sCTF induced dysfunction of endosomes in Down syndrome and Alzheimer's disease. Mol Psych (2015) in press.
147. Cossec JC, Simon A, Marquer C, Moldrich RX, Leterrier C, Rossier J et al. Clathrin-dependent APP endocytosis and Abeta secretion are highly sensitive to the level of plasma membrane cholesterol. Biochim Biophys Acta 1801: 846-852 (2010).
148. Nyakas C, Granic I, Halmy LG, Banerjee P, Luiten PG. The basal forebrain cholinergic system in aging and dementia. Rescuing cholinergic neurons from neurotoxic amyloid-beta42 with memantine. Behav Brain Res 221(2): 594-603 (2011).
149. Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int 54(2): 111-8 (2009).
150. Trazzi S, Fuchs C, Valli E, Perini G, Bartesaghi R, Ciani E. The amyloid precursor protein (APP) triplicated gene impairs neuronal precursor differentiation and neurite development through two different domains in the Ts65Dn mouse model for Down syndrome. J Biol Chem 288(29): 20817-29 (2013).
151. Trazzi S, Fuchs C, De Franceschi M, Mitrugno VM, Bartesaghi R, Ciani E. APP-dependent alteration of GSK3beta activity impairs neurogenesis in the Ts65Dn mouse model of Down syndrome. Neurobiol Dis 67: 24-36 (2014).
152. Begenisic T, Baroncelli L, Sansevero G, Milanese M, Bonifacino T, Bonanno G, et al. Fluoxetine in adulthood normalizes GABA release and rescues hippocampal synaptic plasticity and spatial memory in a mouse model of Down syndrome. Neurobiol Dis 63: 12-9 (2014).
153. Heinen M, Hettich MM, Ryan DP, Schnell S, Paesler K, Ehninger D. Adult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome. Neural Plast 2012: 467251 (2012).
154. Richards SJ, Edwards P, Dunnett SB. Animal models of the neuropathology observed in Alzheimer's disease and Down syndrome. Prog Clin Biol Res 379: 245-58 (1992).
155. Streit WJ, Braak H, Xue QS, Bechmann I. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathol 118(4): 475-85 (2009).
156. van Leeuwen FW, van Tijn P, Sonnemans MA, Hobo B, Mann DM, Van Broeckhoven C, et al. Frameshift proteins in autosomal dominant forms of Alzheimer disease and other tauopathies. Neurology 66(2 Suppl 1): S86-92 (2006).
157. Qian W, Jin N, Shi J, Yin X, Jin X, Wang S, et al. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) enhances tau expression. J Alzheimers Dis 37(3): 529-38 (2013).
158. Rachubinski AL, Maclean KN, Evans JR, Bjugstad KB. Modulating cognitive deficits and tau accumulation in a mouse model of aging Down syndrome through neonatal implantation of neural progenitor cells. Exp Gerontol 47(9): 723-33 (2012).
159. German DC, Eisch AJ. Mouse models of Alzheimer's disease: insight into treatment. Rev Neurosci 15(5): 353-69 (2004).
160. King DL, Arendash GW. Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months. Physiol Behav 75(5): 627-42 (2002).
161. Resende R, Moreira PI, Proenca T, Deshpande A, Busciglio J, Pereira C, et al. Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease. Free Radic Biol Med 44(12): 2051-7 (2008).
162. Bilkei-Gorzo A. Genetic mouse models of brain ageing and Alzheimer's disease. Pharmacol Ther 142(2): 244-57 (2014).
163. Morgan D. Amyloid, memory and neurogenesis. Exp Neurol 205(2): 330-5 (2007).
164. Alamed J, Wilcock DM, Diamond DM, Gordon MN, Morgan D. Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nat Protoc 1(4): 1671-9 (2006).
165. Scholtzova H, Wadghiri YZ, Douadi M, Sigurdsson EM, Li YS, Quartermain D, et al. Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging. J Neurosci Res 86(12): 2784-91 (2008).
166. Lott IT, Head E. Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol Aging. 26(3): 383-9 (2005).
167. Griffin WS. Inflammation and neurodegenerative diseases. Am J Clin Nutr 83(2): 470S-474S (2006).
168. Wenk GL, McGann K, Mencarelli A, Hauss-Wegrzyniak B, Del Soldato P, Fiorucci S. Mechanisms to prevent the toxicity of chronic neuroinflammation on forebrain cholinergic neurons. Eur J Pharmacol 402(1-2): 77-85 (2000).
169. Carnevale D, De Simone R, Minghetti L. Microglia-neuron interaction in inflammatory and degenerative diseases: role of cholinergic and noradrenergic systems. CNS Neurol Disord Drug Targets 6(6): 388-97 (2007).
170. Zassler B, Weis C, Humpel C. Tumor necrosis factor-alpha triggers cell death of sensitized potassium chloride-stimulated cholinergic neurons. Brain Res Mol Brain Res 113(1-2): 78-85 (2003).
171. Heneka MT, Galea E, Gavriluyk V, Dumitrescu-Ozimek L, Daeschner J, O'Banion MK, et al. Noradrenergic depletion potentiates beta-amyloid-induced cortical inflammation: implications for Alzheimer's disease. J Neurosci 22(7): 2434-42 (2002).
172. Appleby BS, Cummings JL. Discovering new treatments for Alzheimer's disease by repurposing approved medications. Curr Top Med Chem 13(18): 2306-27 (2013).
173. Cuello AC, Ferretti MT, Leon WC, Iulita MF, Melis T, Ducatenzeiler A, et al. Early-stage inflammation and experimental therapy in transgenic models of the Alzheimer-like amyloid pathology. Neurodegener Dis 7(1-3): 96-8 (2010).
174. Hunter CL, Bachman D, Granholm AC. Minocycline prevents cholinergic loss in a mouse model of Down's syndrome. Ann Neurol 56(5): 675-88 (2004).
175. Parihar MS, Hemnani T. Alzheimer's disease pathogenesis and therapeutic interventions. J Clin Neurosci 11(5): 456-67 (2004).
176. Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PL, Siedlak SL, et al. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 70(5): 2212-5 (1998).
177. Jovanovic SV, Clements D, MacLeod K. Biomarkers of oxidative stress are significantly elevated in Down syndrome. Free Radic Biol Med 25(9): 1044-8 (1998).
178. Parisotto EB, Garlet TR, Cavalli VL, Zamoner A, da Rosa JS, Bastos J, et al. Antioxidant intervention attenuates oxidative stress in children and teenagers with Down syndrome. Res Dev Disabil 35(6): 1228-36 (2014).
179. Behar TN, Colton CA. Redox regulation of neuronal migration in a Down Syndrome model. Free Radic Biol Med 35(6): 566-75 (2003).
180. Bambrick LL, Fiskum G. Mitochondrial dysfunction in mouse trisomy 16 brain. Brain Res 1188: 9-16 (2008).
181. Busciglio J, Yankner BA. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 378(6559): 776-9 (1995).
182. Sung S, Yao Y, Uryu K, Yang H, Lee VM, Trojanowski JQ, et al. Early vitamin E supplementation in young but not aged mice re duces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J 18(2): 323-5 (2004).
183. Lott IT, Doran E, Nguyen VQ, Tournay A, Head E, Gillen DL. Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation. Am J Med Genet A 155A(8): 1939-48 (2011).
184. Giacobini E. Present and future of Alzheimer therapy. J Neural Transm Suppl 59: 231-42 (2000).
185. Prasher VP. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population. Int J Geriatr Psychiatry 19(6): 509-15 (2004).
186. Kondoh T, Kanno A, Itoh H, Nakashima M, Honda R, Kojima M, et al. Donepezil significantly improves abilities in daily lives of female Down syndrome patients with severe cognitive impairment: a 24-week randomized, double-blind, placebo-controlled trial. Int J Psychiatry Med 41(1): 71-89 (2011).
187. Villarroya M, Garcia AG, Marco JL. New classes of AChE inhibitors with additional pharmacological effects of interest for the treatment of Alzheimer's disease. Curr Pharm Des 10(25): 3177-84 (2004).
188. Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol 2(9): 539-47 (2003).
189. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352(23): 2379-88 (2005).
190. Costa AC, Scott-McKean JJ. Prospects for improving brain function in individuals with Down syndrome. CNS Drugs 27(9): 679-702 (2013).
191. Heise I, Fisher SP, Banks GT, Wells S, Peirson SN, Foster RG, et al. Sleep-like behavior and 24-h rhythm disruption in the Tc1 mouse model of Down syndrome. Genes Brain Behav 14(2): 209-16 (2015).
192. Heller HC, Salehi A, Chuluun B, Das D, Lin B, Moghadam S, et al. Nest building is impaired in the Ts65Dn mouse model of Down syndrome and rescued by blocking 5HT2a receptors. Neurobiol Learn Mem 116: 162-71 (2014).
193. Sahun I, Marechal D, Pereira PL, Nalesso V, Gruart A, Garcia JM, et al. Cognition and hippocampal plasticity in the mouse is altered by monosomy of a genomic region implicated in Down syndrome. Genetics 197(3): 899-912 (2014).
194. Smith GK, Kesner RP, Korenberg JR. Dentate gyrus mediates cognitive function in the Ts65Dn/DnJ mouse model of Down syndrome. Hippocampus 24(3): 354-62 (2014).
195. Galdzicki Z, Siarey RJ. Understanding mental retardation in Down's syndrome using trisomy 16 mouse models. Genes Brain Behav 2(3): 167-78 (2003).
196. Coussons-Read ME, Crnic LS. Behavioral assessment of the Ts65Dn mouse, a model for Down syndrome: altered behavior in the elevated plus maze and open field. Behav Genet 26(1): 7-13 (1996).
197. Kleschevnikov AM, Belichenko PV, Faizi M, Jacobs LF, Htun K, Shamloo M, et al. Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists. J Neurosci 32(27): 9217-27 (2012).
198. Ash JA, Velazquez R, Kelley CM, Powers BE, Ginsberg SD, Mufson EJ, et al. Maternal choline supplementation improves spatial mapping and increases basal forebrain cholinergic neuron number and size in aged Ts65Dn mice. Neurobiol Dis 70: 32-42 (2014).
199. Tabesh A, Jensen JH, Ardekani BA, Helpern JA. Estimation of tensors and tensor-derived measures in diffusional kurtosis imaging. Magn Reson Med 65(3): 823-36 (2011).
200. Rueda N, Florez J, Martinez-Cue C. Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome. Neurosci Lett 433(1): 22-7 (2008).
201. Costa AC, Scott-McKean JJ, Stasko MR. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology 33(7): 1624-32 (2008).
202. Rueda N, Llorens-Martin M, Florez J, Valdizan E, Banerjee P, Trejo JL, et al. Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome. J Alzheimers Dis 21(1): 277-90 (2010).
203. Bennett FC, McClelland S, Kriegsmann EA, Andrus LB, Sells CJ. Vitamin and mineral supplementation in Down's syndrome. Pediatrics 72(5): 707-13 (1983).
204. Clark S, Schwalbe J, Stasko MR, Yarowsky PJ, Costa AC. Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome. Exp Neurol 200(1): 256-61 (2006).
205. De la Torre R, De Sola S, Pons M, Duchon A, de Lagran MM, Farre M, et al. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans. Mol Nutr Food Res 58(2): 278-88 (2014).